|
Evaluating Immune Function Tests in People with HIV Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about Evaluating Immune Function Tests in People with HIV conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Evaluating Immune Function Tests in People with HIV Clinical research trials and Evaluating Immune Function Tests in People with HIV health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like Evaluating Immune Function Tests in People with HIV. Evaluating Immune Function Tests in People with HIV Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a Evaluating Immune Function Tests in People with HIV clinical trial. Subjects frequently get the best healthcare possible for their Evaluating Immune Function Tests in People with HIV condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "E" Clinical Trials Conditions > Evaluating Immune Function Tests in People with HIV  Evaluating Immune Function Tests in People with HIV
Evaluating Immune Function Tests in People with HIV
For Condition: HIV Infections
Status: Recruiting
Sponsor(s): National Institute of Allergy and Infectious Diseases (NIAID) ,
Synopsis: Some people’s immune systems are able to control HIV infection without anti-HIV drugs. Other people with HIV must take drugs to prevent the virus from destroying their immune systems. There are many different laboratory tests that measure immune function in people with HIV. This study will compare some of these tests to see if they consistently measure differences between people who control the HIV without anti-HIV drugs and those who must take drugs.
Details: The efficiency of the immune response to HIV antigens is the critical feature that allows some individuals with chronic HIV infection to maintain low level viremia (less than 3000 copies/ml). The fundamental measurement of this response is the steady state level of viremia in the absence of antiretroviral drugs. However, using this clinical endpoint in vaccine and drug trials is time-consuming. Several laboratory assays of HIV T cell function have been developed to measure the key characteristics of an efficient immune response. This study will evaluate these assays in two distinct patient populations. Two patient cohorts will be followed in this study. Cohort A will enroll patients who are stable on highly active antiretroviral therapy (HAART). These patients will have been on the same HAART regimen for at least 9 months prior to study entry. Cohort B will enroll patients with chronic HIV infection and efficient immune control. These patients will have not been on any antiretroviral drugs for at least 6 months and will have viral loads less than 3,000 copies/ml. Participants in both cohorts will have blood drawn at study entry and Weeks 12 and 24. Blood samples will be used for CD4/CD8 cell count, plasma HIV-1 RNA, and immunologic assays.
Eligibility:
Study Type: Observational, Natural History, Defined Population, Prospective Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria for Cohorts A and B: - HIV-1 infection - CD4 cell count > 300 cells/mm3 within 60 days prior to study entry - Negative pregnancy test within 14 days of starting study - Agree to use acceptable methods of contraception while in study Inclusion Criteria for Cohort A (Stable HAART) Only: - Stable HAART regimen, defined as the suppression of viral load to undetectable levels, for at least 9 months prior to study entry - Viral load < 75 copies/ml on at least three occasions within 9 months prior to study entry, with at least one of these values obtained between 6 and 9 months prior to study entry - No single viral load >= 75 copies/ml within 9 months prior to study entry Inclusion Criteria for Cohort B (Efficient Immune Control) Only: - Not taking any antiretroviral drugs for at least 6 months prior to study entry - Meets study definition of efficient immune control (generally HIV-1 viral load < 3,000 copies/ml, with some exceptions) Exclusion Criteria: - Pregnancy or breast-feeding - Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements - History of an AIDS-defining opportunistic infection
Total Enrollment: 54
Location and Contact Information:
Overall Study Official:
R.Bucy, Study Chair, University of Alabama, Birmingham
Case Western Reserve University *Recruiting*
Cleveland, Ohio, 44106-5083
United States
Recruiting Michael Chance 216-844-8051
University of Pittsburgh *Recruiting*
Pittsburgh, Pennsylvania, 15213-2582
United States
Recruiting Christine Tripoli 412-647-0771
University of Pittsburgh *Recruiting*
Pittsburgh, Pennsylvania, 15213-2582
United States
Recruiting Christine Tripoli 412-647-0771
Rush-Presbyterian/St. Lukes *Recruiting*
Chicago, Illinois, 60612-3806
United States
Recruiting Jan Fritsche 312-942-4810
University of Miami *Recruiting*
Miami, Florida, 33136-1013
United States
Recruiting Leslie Thompson 305-243-3838
University of Alabama at Birmingham *Recruiting*
Birmingham, Alabama, 35924-2050
United States
Recruiting Karen Savage 202-975-7925
Additional Information:
Study ID Numbers: ACTG A5181;
Study Start Date:
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00067795
Other Hiv Infections Studies:
1. A Study of Delavirdine Used Together with Other Anti-HIV Drugs in HIV-Infected Patients
2. A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma
3. A Study of Lobucavir in Patients with AIDS
4. A Pilot Study of Oral Clindamycin and Pyrimethamine for the Treatment of Toxoplasmic Encephalitis in Patients With AIDS
5. Metformin and Rosiglitazone, Alone or in Combination, in HIV-Infected Patients with Insulin and Fat Abnormalities
Related Studies:
Other HIV Infections Clinical Trials
Other Pennsylvania Clinical Trials
Other Pittsburgh Clinical Trials
Evaluating Immune Function Tests in People with HIV
|
|
|
|
|
|
|
|
